Title |
Relating relapse and T2 lesion changes to disability progression in multiple sclerosis: a systematic literature review and regression analysis
|
---|---|
Published in |
BMC Neurology, November 2013
|
DOI | 10.1186/1471-2377-13-180 |
Pubmed ID | |
Authors |
Kyle Fahrbach, Rachel Huelin, Amber L Martin, Edward Kim, Homa B Dastani, Stephen Rao, Manoj Malhotra |
Abstract |
In the treatment of multiple sclerosis (MS), the most important therapeutic aim of disease-modifying treatments (DMTs) is to prevent or postpone long-term disability. Given the typically slow progression observed in the majority of relapsing-remitting MS (RRMS) patients, the primary endpoint for most randomized clinical trials (RCTs) is a reduction in relapse rate. It is widely assumed that reducing relapse rate will slow disability progression. Similarly, MRI studies suggest that reducing T2 lesions will be associated with slowing long-term disability in MS. The objective of this study was to evaluate the relationship between treatment effects on relapse rates and active T2 lesions to differences in disease progression (as measured by the Expanded Disability Status Scale [EDSS]) in trials evaluating patients with clinically isolated syndrome (CIS), RRMS, and secondary progressive MS (SPMS). |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Egypt | 1 | 33% |
Unknown | 2 | 67% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Practitioners (doctors, other healthcare professionals) | 2 | 67% |
Members of the public | 1 | 33% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 1 | 1% |
Spain | 1 | 1% |
Brazil | 1 | 1% |
Unknown | 89 | 97% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 13 | 14% |
Other | 10 | 11% |
Researcher | 10 | 11% |
Student > Bachelor | 9 | 10% |
Student > Ph. D. Student | 8 | 9% |
Other | 16 | 17% |
Unknown | 26 | 28% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 36 | 39% |
Neuroscience | 12 | 13% |
Biochemistry, Genetics and Molecular Biology | 3 | 3% |
Pharmacology, Toxicology and Pharmaceutical Science | 2 | 2% |
Sports and Recreations | 2 | 2% |
Other | 8 | 9% |
Unknown | 29 | 32% |